Search

Displaying results 1141 - 1150 of 7604 in total
  1. Drug

    Cyclothiazide

    go.drugbank.com/drugs/DB00606
    Approved

    It is also indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension. … The antihypertensive mechanism of cyclothiazide is less well understood although it may be mediated through its action on carbonic anhydrases in the smooth muscle or through its action on the large-conductance

  2. Drug

    Rezafungin

    go.drugbank.com/drugs/DB16310
    ApprovedInvestigational

    [L45633,L45658] It was subsequently approved in the EU in November of the same year. [L52745] … [A258403] In March 2023, the FDA approved rezafungin for injection for the treatment of candidemia and invasive candidiasis in adults with limited or no alternative treatment options.

  3. Target

    Vascular endothelial growth factor A, long form

    go.drugbank.com/bio_entities/BE0000163
    TargetHumans

    Participates in the induction of key genes involved in the response to hypoxia and in the induction of angiogenesis such as HIF1A (PubMed:35455969). Involved in protecting cells from hypoxia-mediated cell death (By similarity)

    Polypeptides: Vascular endothelial growth factor A, long form
  4. Drug

    Lebrikizumab

    go.drugbank.com/drugs/DB11914
    ApprovedInvestigational

    years and older with a body weight of at least 40 kg. … [A262874,A262879] On November 17, 2023, lebrikizumab was approved by the EMA under the brand name EBGLYSS for the treatment of moderate-to-severe atopic dermatitis in adult and adolescent patients 12

    Categories: Agents for Dermatitis, Excluding Corticosteroids
  5. Drug

    Penpulimab

    go.drugbank.com/drugs/DB16747
    ApprovedInvestigational

    [A273843,A273848] Penpulimab-kcqx was approved by the US FDA in April 2025 for the treatment of nasopharyngeal carcinoma in select patients.[L52993,L52998] … [A273848] In order to further reduce the risk of toxicities and improve efficacy, penpulimab was designed with Fc mutations in order to eliminate Fc receptor and complement-mediated effector function,

  6. Drug

    Methyltestosterone

    go.drugbank.com/drugs/DB06710
    ApprovedInvestigational

    A synthetic anabolic steroid used for treating men with testosterone deficiency or similar androgen replacement therapies. … Methyltestosterone is a schedule III drug in the US.

  7. Drug

    Dapsone

    go.drugbank.com/drugs/DB00250
    ApprovedInvestigational

    A sulfone active against a wide range of bacteria but mainly employed for its actions against mycobacterium leprae.

    Categories: Antiinfectives for Systemic Use, Drugs for Treatment of Lepra
  8. Drug

    Atogepant

    go.drugbank.com/drugs/DB16098
    ApprovedInvestigational

    [L38814] While its approval was predated by two other members of the same drug family, namely [ubrogepant] and [rimegepant], these agents are indicated only for abortive migraine therapy - atogepant is … novel in that it is the first and only oral CGRP antagonist approved for preventative use in migraine.

  9. Drug

    Brimonidine

    go.drugbank.com/drugs/DB00484
    ApprovedInvestigational

    [A178945] Thus brimonidine is an effective and safe alternative to beta-blockers, in patients with, or at high risk for, cardiopulmonary disease. … [A178948] The topical form of brimonidine was approved by the FDA in August 2013 for the symptomatic treatment of persistent facial erythema of rosacea in adults.

    Mixtures: Brim-Dor PF, Tim-Brim-Dor PFProducts: NOR TENZ
  10. Drug

    Bromocriptine

    go.drugbank.com/drugs/DB01200
    ApprovedInvestigationalWithdrawn

    In 1995, the FDA withdrew the approval of bromocriptine mesylate for the prevention of physiological lactation after finding that bromocriptine was not shown to be safe for use. … [L43942,L43947] It continues to be used for the indications mentioned above.

    Categories: Heterocyclic Compounds with 4 or More Rings